While the majority of enzalutamide-treated patients with nonmetastatic castration-resistant prostate cancer in PROSPER had some increase from nadir in prostate-specific antigen at the time of radiographic progression, the median absolute increase was less than the Prostate Cancer Working Group 2 threshold of 2 ng/mL.
- Nonmetastatic castration-resistant prostate cancer
- Prostate Cancer Working Group 2
- Prostate-specific antigen progression
ASJC Scopus subject areas